SAN DIEGO, CA -- (MARKET WIRE) -- 01/24/12 -- Cytori
Therapeutics (NASDAQ: CYTX) announced today the publication
of previously reported six-month outcomes from APOLLO, the
Company's European clinical trial evaluating
adipose-derived stem and regenerative cells (ADRCs) in
patients with acute myocardial infarction (heart attack or
AMI), as Research Correspondence in the
Journal of the American College of Cardiology. The APOLLO
trial was a 14-patient, prospective, randomized,
double-blind, placebo-controlled, feasibility trial (Phase
I/IIA) evaluating autologous ADRCs extracted with the
Company's proprietary Celution® System for the treatment
of patients suffering from acute myocardial infarction.
In the APOLLO trial all patients were treated with
standard-of-care and subsequently underwent an abdominal
liposuction.
Each patient's adipose tissue was processed by the
Celution® System where ADRCs were extracted, washed and
concentrated into a syringe of clinical grade cells. Within
36 hours of the myocardial infarction and no longer than 24
hours after undergoing percutaneous coronary intervention,
patients received an injection of either 20 million ADRCs
(n=10) or a placebo (n=4).
The publication reported:
Cytori Therapeutics Inc Deutsche Boerse AG
Equities
US23283K1051
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
|
1st Jan change | Capi. | |
---|---|---|
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- PSTV Stock
- Stock
- News Cytori Therapeutics Inc
- Cytori Therapeutics Inc. : Adipose Stem Cell Heart Attack Trial Data Published in Journal of the American College of Cardiology; Cytori's APOLLO Trial Demonstrated Safety & Feasibility and Improvements in Cardiac Function